home > research channels > sectors > pharma > reports

 
Reports Archive   Year   
Date Title Pages Source Download
Dec-17 The generic price fixing iceberg just got bigger   11 Edelweiss Securities
Nov-17 Customer consolidation: Horizontal to vertical   12 Edelweiss Securities
Oct-17 Sequential Improvement Expected; Long-term Prospects Remain Intact   6 Reliance Securities Ltd.
Oct-17 2QFY18E Results Preview   9 HDFC Securities
Oct-17 Weak flu season, regulatory pressure to impact earnings   8 Edelweiss Securities
Oct-17 USFDA fillip to complex generics   11 Emkay Research
Sep-17 Prescription Charts of Interest - August 2017   5 Nirmal Bang
Sep-17 IPM secondary sales growth up marginally   22 Motilal Oswal
Sep-17 Competition commission lens on Healthcare sector   2 Emkay Research
Sep-17 Evolving US generic market to plummet profitability levels of Indian pharmaceutical companies   7 CARE Research
Aug-17 Govt calls for better enforcement   2 Emkay Research
Aug-17 Time to look at Pharma Funds   5 HDFC Securities
Aug-17 IPM secondary sales decline in July   22 Motilal Oswal
Aug-17 Draft Pharmaceutical Policy;   4 Emkay Research
Aug-17 New pharma policy on the anvil   5 Edelweiss Securities
Jul-17 GST impact, US price erosion to weigh on Q1   15 ICICI direct.com
Jul-17 Indian Pharmaceuticals Industry   10 CARE Research
Jul-17 India Pharma: Q1 preview   11 Anand Rathi
Jul-17 Pharmaceuticals - 1QFY18 Results Preview   9 HDFC Securities
Jul-17 Q1FY18 result preview   9 ICICI Securities
Jul-17 Earnings to remain range-bound   2 Nirmal Bang
Jul-17 INR appreciation further mars lethargic performance   15 Edelweiss Securities
Jul-17 Limited reasons to cheer FDA...   3 Emkay Research
Jun-17 US FDA introduces policy to expedite approval process   4 Motilal Oswal
Jun-17 Enough Headroom To Grow For Indian Generic Companies   11 Nirmal Bang
Jun-17 US drug pricing task force spells bad news for generic companies   2 Emkay Research
Jun-17 US price pressure to dent near term growth   30 ICICI direct.com
Jun-17 Base business pressures to remain   10 IIFL
Jun-17 US FDA shows it has a bark and a bite   2 Emkay Research
Jun-17 CDSCO bans FDC approval by state FDA¿s...   2 Emkay Research
Jun-17 CDSCO bans FDC approval by state FDA¿s...   2 Emkay Research
Jun-17 Pharma¿s 4Q debacle: Our view   13 HDFC Securities
May-17 IPM delivered moderate growth in April 2017   22 Motilal Oswal
May-17 US pricing pressure steeper than expected   27 ICICI direct.com
May-17 India PharmaScope   7 Religare Research
May-17 Time for Indian Pharma R&D Ratings to shift its gears to match with the global players   5 CARE Research
May-17 Healthcare industry in government crosshairs   10 Emkay Research
May-17 Down but not out   77 Anand Rathi
Apr-17 Feedback of Doctors/Chemists on Govt Order to Prescribe Generics   4 Nirmal Bang
Apr-17 4QFY17E Results Preview   9 HDFC Securities
Feb-17 Biosimilar Opportunity For Indian Players   3 Nirmal Bang
Feb-17 Demonetization impact subsides but full recovery in IPM not clear   21 Emkay Research
Feb-17 Q3 Review: Margin beat but core EBITDA weak   9 Religare Research
Feb-17 Speeding up FDA approvals, negative for generics; positive for CRAMS   3 Emkay Research
Jan-17 3QFY17E Results Preview   8 HDFC Securities
Jan-17 Expect mixed bag performance   12 Anand Rathi
Jan-17 Have USFDA inspections on Indian facilities peaked out?   4 Emkay Research
Jan-17 Muted performance to continue   16 Edelweiss Securities
Jan-17 Pricing pressure in the US to keep growth under check   20 Motilal Oswal
Jan-17 Q3 Preview: Anaemic Quarte   9 Religare Research
Jan-17 Q3FY17 result preview   9 ICICI direct.com
Jan-17 Range-bound Performance Likely   2 Nirmal Bang
Jan-17 Seasonality, currency ban cramp Dec sales   11 Religare Research
Jan-17 Some companies surfacing inspite of headwinds   7 IDBI Capital
Jan-17 Truth vs Hype   143 HDFC Securities